Clinical Features of Bilateral Progressive Hearing Loss Associated with Myeloperoxidase-Antineutrophil Cytoplasmic Antibody

In this study, we analyzed the clinical features, diagnostic criteria, treatment, and outcome of atypical bilateral progressive hearing loss associated with myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA). The evaluation was made by audiogram and laboratory data in 6 cases treated at Hokkaido University Hospital. We measured MPO-ANCA by enzyme-linked immunosorbent assay; the result was positive in all cases. The hearing loss developed bilaterally and progressed to total deafness within several weeks. The onset of hearing loss was not simultaneous in the 2 ears. Methylprednisolone pulse therapy was effective in 9 ears. Three ears showed no improvement; 2 of the 3 ears had already exhibited total deafness at the first visit. After the treatment. the titer of MPO-ANCA decreased in all patients. The level of MPO-ANCA should be tested in patients with bilateral progressive hearing loss of unknown origin and can be used as a marker of the disease's activity.

[1]  D. Schroeder,et al.  Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. , 2002, Clinical immunology.

[2]  A. Ishiyama,et al.  Otological Manifestations of Churg‐Strauss Syndrome , 2001, The Laryngoscope.

[3]  S. Fukuda,et al.  Myeloperoxidase-antineutrophil cytoplasmic antibody-associated sensorineural hearing loss. , 2001, Auris, nasus, larynx.

[4]  R. Falk,et al.  Small-vessel vasculitis. , 1997, The New England journal of medicine.

[5]  R. Falk,et al.  Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. , 1996, Journal of the American Society of Nephrology : JASN.

[6]  R. Falk,et al.  Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. , 1996, Journal of the American Society of Nephrology : JASN.

[7]  R. Porter.  Nomenclature of Systemic Vasculitides: Proposal of an International Consensus Conference , 1995 .

[8]  Y. Arimura,et al.  Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis. , 1993, Clinical nephrology.

[9]  Guy Hoffman,et al.  Wegener Granulomatosis: An Analysis of 158 Patients , 1992, Annals of Internal Medicine.

[10]  C. Kallenberg,et al.  Association of autoantibodies to myeloperoxidase with different forms of vasculitis. , 2010, Arthritis and rheumatism.

[11]  J. Tschopp,et al.  Wegener's autoantigen decoded , 1990, Nature.

[12]  P. Sharp,et al.  Inner ear autoantibodies in patients with rapidly progressive sensorineural hearing loss , 1990, The Laryngoscope.

[13]  H. Kempf.  Ear involvement in Wegener's granulomatosis. , 1989, Clinical otolaryngology and allied sciences.

[14]  M. Paparella,et al.  Systemic vasculitis: A temporal bone histopathologic study , 1989, The Laryngoscope.

[15]  B. Mccabe.  Autoimmune inner ear disease: therapy. , 1989, The American journal of otology.

[16]  R. Falk,et al.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. , 1988, The New England journal of medicine.

[17]  T. H. The,et al.  AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSIS , 1985, The Lancet.

[18]  B. Nicklasson,et al.  Wegener's granulomatosis presenting as otitis media , 1982, The Journal of Laryngology & Otology.

[19]  J. Mathews,et al.  AUTOIMMUNE SENSORINEURAL HEARING LOSS , 1980, The Lancet.

[20]  B. Mccabe.  Autoimmune Sensorineural Hearing Loss , 1979, The Annals of otology, rhinology, and laryngology.